Evercore ISI Group Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $46

Evercore ISI Group has initiated coverage on Damora Therapeutics (NASDAQ: DMRA) with an Outperform rating. The firm has set a price target of $46 for the company's stock.